Benitec takes on deadly genes
James EyersSenior Reporter
Benitec last week stitched up a research agreement with City of Hope, a leading cancer research and treatment centre in Los Angeles.
The Queensland-based biotech which has developed a proprietary technology known as "DNA-directed RNA interference", which targets DNA and attempts to "silence" the genes responsible for serious diseases will fund the initial research and potentially receive a revenue stream if a treatment is commercialised.
Loading...
James Eyers writes on banking, payments and fintech. He is a former legal and investment banking editor at the AFR, has degrees in commerce and law from UNSW, and is co-author of Buy now, pay later: The extraordinary story of Afterpay Connect with James on Twitter. Email James at jeyers@afr.com.au
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Politics
Fetching latest articles